What is the total addressable market for Burna AI?

$15 to $20 billion+ across the drug lifecycle, distributed across five layers. Clinical trial AE grading: $4 billion+ (manual grading at a significant share of clinical trial operating costs across thousands of global oncology trials). Patient self-reporting and RTM: $1 to $2 billion. Postmarket pharmacovigilance: $8 to $10 billion+ (global PV market; FDA receives 2 million+ adverse drug reaction reports annually, processing mandated by regulation for every approved drug, indefinitely). Safety signal analytics: $1 to $2 billion. Protocol Safe (pharma sponsor architecture): $500 million to $1.5 billion today, growing to $2 to $5 billion by 2030.